Development of T-cell engagers selective for cells co-expressing two antigens
T cell-engaging bispecific antibodies (TCEs) are clinically effective treatments for hematological cancers. While the utility of TCEs in solid malignancies is being explored, toxicities arising from antigen expression on normal tissues have slowed or halted several clinical trials. Here, we describe...
Saved in:
Main Authors: | Danielle M. Dicara (Author), Sunil Bhakta (Author), Mary Ann Go (Author), James Ziai (Author), Ron Firestein (Author), Bill Forrest (Author), Chen Gu (Author), Steven R. Leong (Author), Genee Lee (Author), Shang-Fan Yu (Author), Andrew G. Polson (Author), Nicholas J. Agard (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Minor Histocompatibility Antigen-Specific T Cells
by: Corinne Summers, et al.
Published: (2020) -
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors
by: Vanesa Alonso-Camino, et al.
Published: (2013) -
Implications of Antigen Selection on T Cell-Based Immunotherapy
by: Faye A. Camp, et al.
Published: (2021) -
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
by: Yuexin Xu, et al.
Published: (2021) -
Crystalline silica activates the T-cell and the B-cell antigen receptor complexes and induces T-cell and B-cell proliferation
by: Theodoros Eleftheriadis, et al.
Published: (2019)